Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan. Soon thereafter, REPROCELL products were employed by Professor Shinya Yamanaka (Nobel Laureate, 2012) during his pioneering research on induced pluripotent stem cell (iPSC) technologies at Kyoto University. REPROCELL was the first company to offer iPSC-derived human cardiomyocytes, hepatocytes and neuronal cells for research applications. As a market leader, with a portfolio of cells, culture media and reagents, the company was listed on the Japan JASDAQ / Growth stock market in 2013.
In recent years, many commercial opportunities and applications were developed directly upstream and downstream of the iPSC workflow. Therefore, the company aggressively expanded its busines through a series of acquistions to become the REPROCELL Group Companies. Each company it acquired possessed intellectual property and knowledge that helps to amplify the value of the organization by complementing the capabilities of the others. Together, a workflow has emerged that spans from human tissue acquisition (Bioserve®, Biopta®), to iPSC reprogramming (Stemgent®), cell differentiation (REPROCELL), in vitro tissue modelling with 3D technology (Reinnervate®), and assay development for applications in drug discovery (Biopta®). More recently, these companies have been integrated and consolidated to regional offices, and the names converted to product and service brands. In the stem cell and drug discovery “market- space”, no other company has this broad combination of expertise that can be applied to nearly the entire span of the drug discovery pipeline, and even to new areas of regenerative medicine. For a concise summary of REPROCELL's overall capabilities, you can reference our Corporate Capabilities Guide.
In the last few years, as a company REPROCELL has evolved in terms of global infrastructure and the corporate organization and strategy. By leveraging the our knowledge-base of stem cell technologies, REPROCELL has planned a future that directly involves pursuit of regenerative medicine market opportunities. This evolution has compelled us to restructure, modify and define our future vision. The REPROCELL Corporate Profile Guide concisely explains our current organization and provides a guideline for corporate development and operations. A brief summary of the REPROCELL vision, mission and value statements are shown below.
REPROCELL Global Corporate Offices:
Improving human health through biomedical innovation and discovery.
We empower research scientists and medical professionals to improve the quality of human life by providing unique products and services that accelerate breakthrough medical technologies and therapies. We improve efficiency and add value with our collaborative approach and custom solutions that help conquer the technical challenges of drug development, human diagnostics, and regenerative medicine.
QUALITY: It is at the core of all we do. Investments in people and infrastructure drive quality thinking, quality products and services, and quality customer and patient experiences.
INNOVATION: Technical advancement requires that we remain flexible and agile. We are forward- thinking and embody the process of continuous improvement. We are dedicated to cultivating and commercializing cutting-edge research and advanced medical technologies to improve human health.
TRUST: As skilled experts, we are trusted partners in our customer’s success. We seek to build and maintain their trust through honest effort, communication and transparency.
VALUE: We add value by providing tools and services that de-risk, enable and accelerate customer research workflows and medical healthcare applications.
CUSTOMER FOCUS: We help solve critical challenges and provide customized results by listening, designing and implementing solutions to address the unique needs of our clients.